Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00795821 · ClinicalTrials.gov registry record · Phase 2
A Study in Adult Patients With Major Depressive Disorder
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 495
- Enrollment target
NCT00795821 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 495 participants.
The verdict
NCT00795821, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 495 participants
- Enrollment target
Study Summary
The purpose of this study is to assess whether LY2216684 is superior to placebo in the treatment of adult patients with major depressive disorder.
Interventions
- DRUG Placebo
- DRUG LY2216684
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 495 participants |
| Start Date | 2008-12 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00795821
The ClinicalTrials.gov registry entry for NCT00795821 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 495 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00795821 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00795821 about?
NCT00795821 is a clinical study titled "A Study in Adult Patients With Major Depressive Disorder". The purpose of this study is to assess whether LY2216684 is superior to placebo in the treatment of adult patients with major depressive disorder.
What is the current status of trial NCT00795821?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 495 participants. The study started on 2008-12. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00795821?
The interventions under investigation include: Placebo (DRUG), LY2216684 (DRUG).
Who is sponsoring clinical trial NCT00795821?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.